Drug Profile
Research programme: infectious disease vaccines - IMV
Alternative Names: Bacterial vaccines - IMV; DepoVax™; DPX-Ebola; Malaria vaccine - IMVLatest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator ImmunoVaccine Technologies
- Developer Defence Research and Development Canada; Immunovaccine; IMV; National Institute of Allergy and Infectious Diseases
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Malaria; Viral haemorrhagic fevers
- Discontinued Anthrax; Ebola virus infections; Hepatitis B; Influenza virus infections
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Bacterial-infections in Canada (Parenteral)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Malaria in USA (Parenteral)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Viral-haemorrhagic-fevers in USA (Parenteral)